TY - JOUR
T1 - Diffuse large B-cell lymphoma
T2 - new targets and novel therapies
AU - Cheson, Bruce D.
AU - Nowakowski, Grzegorz
AU - Salles, Gilles
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/4
Y1 - 2021/4
N2 - Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.
AB - Newer, more effective and non-cytotoxic therapies are an unmet need for patients with diffuse large B-cell lymphoma (DLBCL) and other B-cell malignancies. Recently approved agents include polatuzumab with bendamustine and rituximab, selinexor, and tafasitamab plus lenalidomide. Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates. Combinations of targeted therapies should lead to further improvement in the outcome of patients with B-cell malignancies.
UR - http://www.scopus.com/inward/record.url?scp=85103921768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103921768&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00456-w
DO - 10.1038/s41408-021-00456-w
M3 - Review article
C2 - 33820908
AN - SCOPUS:85103921768
SN - 2044-5385
VL - 11
JO - Blood Cancer Journal
JF - Blood Cancer Journal
IS - 4
M1 - 68
ER -